Karyopharm Therapeutics (KPTI) Other Non-Current Assets (2012 - 2025)
Karyopharm Therapeutics (KPTI) reported Other Non-Current Assets of $267000.0 for Q4 2025, down 21.01% on a YoY basis from $338000.0 in Q4 2024, and down 23.71% quarter-over-quarter from $350000.0 in Q3 2025.
Karyopharm Therapeutics (KPTI) Other Non-Current Assets (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Other Non-Current Assets for 14 years, with the latest figure at $267000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets fell 21.01% year-over-year to $267000.0; the trailing twelve-month figure through Dec 2025 stood at $267000.0 (down 21.01% YoY), and the FY2025 full-year result was $267000.0, down 21.01% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $267000.0, down from $350000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.3 million in Q1 2025, with the low at $267000.0 in Q4 2025.
- Historically, Other Non-Current Assets has averaged $520750.0 across 5 years, with a median of $506500.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets slumped 52.45% — and 2025, when it jumped 338.82%.
- Karyopharm Therapeutics' Other Non-Current Assets stood at $637000.0 in 2021, then dropped by 0.63% to $633000.0 in 2022, then tumbled by 52.45% to $301000.0 in 2023, then grew by 12.29% to $338000.0 in 2024, then decreased by 21.01% to $267000.0 in 2025.
- The last three Other Non-Current Assets figures came in at $267000.0 (Q4 2025), $350000.0 (Q3 2025), and $350000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn | 267,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 267,000.00 |
| Sep 30, 2025 | 350,000.00 |
| Jun 30, 2025 | 350,000.00 |
| Mar 31, 2025 | 1.33 Mn |
| Dec 31, 2024 | 338,000.00 |
| Sep 30, 2024 | 306,000.00 |
| Jun 30, 2024 | 304,000.00 |
| Mar 31, 2024 | 304,000.00 |
| Dec 31, 2023 | 301,000.00 |
| Sep 30, 2023 | 381,000.00 |
| Jun 30, 2023 | 387,000.00 |
| Mar 31, 2023 | 634,000.00 |
| Dec 31, 2022 | 633,000.00 |
| Sep 30, 2022 | 626,000.00 |
| Jun 30, 2022 | 631,000.00 |
| Mar 31, 2022 | 636,000.00 |
| Dec 31, 2021 | 637,000.00 |
| Sep 30, 2021 | 639,000.00 |
| Jun 30, 2021 | 639,000.00 |
| Mar 31, 2021 | 718,000.00 |